Eurosurv. Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health

[tetano]

• Susan L Hills[SUP]1[/SUP] , Rebekah A Sutter[SUP]1[/SUP] , Elaine R Miller[SUP]2[/SUP] , Edwin J Asturias[SUP]3[/SUP] , Lin H Chen[SUP]4,5[/SUP] , Beth P Bell[SUP]6[/SUP] , Michael M McNeil[SUP]2[/SUP] , Jeffrey Rakickas[SUP]2[/SUP] , Melinda Wharton[SUP]2[/SUP] , Sarah Meyer[SUP]2[/SUP] , J Erin Staples[SUP]1[/SUP]

​A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.32.2500543